LIFETECH SCI.DL-00000125 (81X) - Total Liabilities
Based on the latest financial reports, LIFETECH SCI.DL-00000125 (81X) has total liabilities worth €1.54 Billion EUR (≈ $1.80 Billion USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check financial resilience of LIFETECH SCI.DL-00000125 to evaluate the company's liquid asset resilience ratio.
LIFETECH SCI.DL-00000125 - Total Liabilities Trend (2021–2025)
This chart illustrates how LIFETECH SCI.DL-00000125's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see balance sheet size of LIFETECH SCI.DL-00000125.
LIFETECH SCI.DL-00000125 Competitors by Total Liabilities
The table below lists competitors of LIFETECH SCI.DL-00000125 ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Luyin Investment Group Co Ltd
SHG:600784
|
China | CN¥2.57 Billion |
|
Chongqing Changan Automobile Co Ltd
SHE:200625
|
China | HK$102.11 Billion |
|
Beijing ZznodeTechnologies Co Ltd
SHE:003007
|
China | CN¥1.29 Billion |
|
HIVE Digital Technologies Ltd.
V:HIVE
|
Canada | CA$64.72 Million |
|
Guizhou Guihang Automotive Components Co Ltd
SHG:600523
|
China | CN¥865.89 Million |
|
Alligo AB Series B
ST:ALLIGO-B
|
Sweden | Skr5.91 Billion |
|
New Found Gold Corp
V:NFG
|
Canada | CA$18.61 Million |
|
Sino-High (China) Co. Ltd.
SHE:301076
|
China | CN¥82.10 Million |
Liability Composition Analysis (2021–2025)
This chart breaks down LIFETECH SCI.DL-00000125's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See 81X net asset quality score to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.57 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.44 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.31 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how LIFETECH SCI.DL-00000125's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for LIFETECH SCI.DL-00000125 (2021–2025)
The table below shows the annual total liabilities of LIFETECH SCI.DL-00000125 from 2021 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | €1.54 Billion ≈ $1.80 Billion |
+7.89% |
| 2024-12-31 | €1.42 Billion ≈ $1.67 Billion |
+3.83% |
| 2023-12-31 | €1.37 Billion ≈ $1.60 Billion |
+78.45% |
| 2022-12-31 | €769.05 Million ≈ $899.10 Million |
+17.66% |
| 2021-12-31 | €653.61 Million ≈ $764.14 Million |
-- |
About LIFETECH SCI.DL-00000125
LifeTech Scientific Corporation, an investment holding company, develops, manufactures, and trades in interventional medical devices for cardiovascular and peripheral vascular diseases and disorders in Mainland China, Europe, Rest of Asia, India, South America, Africa, and internationally. It operates through Structural Heart Diseases Business, Peripheral Vascular Diseases Business, and Cardiac P… Read more